Gastritis: Difference between revisions
(Gastritis - New Page) |
|||
| (20 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
[[File:Gray1046.png|thumb|Stomach anatomy]] | |||
[[File:Illu stomach2.jpg|thumb|Stomach wall anatomy]] | |||
*Inflammation of the stomach lining | *Inflammation of the stomach lining | ||
*May occur acutely or chronically | *May occur acutely or chronically | ||
*May lead to [[ | *May lead to [[peptic ulcer disease]] | ||
*Causes | *Causes | ||
**H. pylori | **[[H. pylori]] | ||
**NSAIDs | **[[NSAIDs]] | ||
** | **[[ETOH]] | ||
**Critical Illness (Cushing ulcer) | **Critical Illness (Cushing ulcer) | ||
*** | ***[[Increased ICP]], stimulation of vagal nuclei, increased secretion of gastric acid | ||
==Clinical Features== | ==Clinical Features== | ||
*Gnawing or burning pain | *Gnawing or burning [[epigastric pain]] | ||
*Nausea | *[[Nausea/vomiting]] | ||
*Early satiety, bloating | *Early satiety, bloating | ||
*Heartburn | *Heartburn | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
{{Abdominal Pain DDX Epigastric}} | |||
== | ==Evaluation== | ||
*CBC ( | [[File:PMC5316417 10120 2016 680 Fig4 HTML.png|thumb|Conventional white-light endoscopic findings for the gastric body. (a) Normal (b) Gastric mucosa with chronic atrophic gastritis associated with HP infection. Visible vessels and an absence of folds in the gastric body mucosa are characteristic of chronic atrophic gastritis.]] | ||
*BMP, LFTs | *CBC (to rule out anemia) | ||
*BMP, [[LFTs]] | |||
*Lipase | *Lipase | ||
* | *Consider: | ||
*?Barium swallow | **[[Acute abdominal series]] | ||
* | **?Barium swallow (upper GI series) | ||
* | **Endoscopy (most will be done as outpatient) | ||
* | **[[RUQ US]] | ||
**[[ECG]]/[[troponin]] | |||
== | ==Management== | ||
*Cessation of NSAIDs and | *Cessation of [[NSAIDs]] and [[ETOH]] | ||
*Eradicate H. pylori if identified in symptomatic | *Eradicate [[H. pylori]] if identified in symptomatic patient | ||
**Triple Therapy: PPI + [[clarithromycin]] 500mg BID + [[amoxicillin]]1g BID x 10-14d | **Triple Therapy: [[PPI]] + [[clarithromycin]] 500mg BID + [[amoxicillin]]1g BID x 10-14d | ||
***[[Metronidazole]] | ***[[Metronidazole]] 500mg BID can be substituted for [[amoxicillin]] in penicillin-allergic individuals | ||
**Quadruple Therapy: PPI + bismuth subsalicylate | **Quadruple Therapy: [[PPI]] + [[bismuth subsalicylate]] 524mg QID + [[metronidazole]] 250mg QID and [[tetracycline]] 500mg QID x 10-14d. | ||
***Can be used in areas of high resistance to clarithromycin or metronidazole | ***Can be used in areas of high resistance to [[clarithromycin]] or [[metronidazole]] | ||
*PPI | *[[PPI]] | ||
**Generally heal ulcers faster than H2 | **Generally heal ulcers faster than [[H2 blocker]]s | ||
**[[Omeprazole]] 20-40mg QD | **[[Omeprazole]] 20-40mg QD | ||
*H2 | *[[H2 blocker]]s | ||
**[[Famotidine]] 20-40mg QD | **[[Famotidine]] 20-40mg QD | ||
**[[Ranitidine]] 75-150mg BID | **[[Ranitidine]] 75-150mg BID | ||
| Line 73: | Line 56: | ||
*Unexplained weight loss | *Unexplained weight loss | ||
*Early satiety | *Early satiety | ||
*Persistent vomiting | *Persistent [[vomiting]] | ||
*Dysphagia | *[[Dysphagia]] | ||
*Anemia or GI bleeding | *[[Anemia]] or [[GI bleeding]] | ||
*Abdominal mass | *Abdominal mass | ||
*Persistent anorexia | *Persistent anorexia | ||
*Jaundice | *[[Jaundice]] | ||
==See Also== | ==See Also== | ||
[[PUD]] | *[[PUD]] | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:GI]] | |||
Latest revision as of 13:34, 2 May 2020
Background
- Inflammation of the stomach lining
- May occur acutely or chronically
- May lead to peptic ulcer disease
- Causes
- H. pylori
- NSAIDs
- ETOH
- Critical Illness (Cushing ulcer)
- Increased ICP, stimulation of vagal nuclei, increased secretion of gastric acid
Clinical Features
- Gnawing or burning epigastric pain
- Nausea/vomiting
- Early satiety, bloating
- Heartburn
Differential Diagnosis
Epigastric Pain
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease with or without perforation
- Gastritis
- Pancreatitis
- Gallbladder disease
- Myocardial Ischemia
- Splenic Infarctionenlargement/rupture/aneurysm
- Pericarditis/Myocarditis
- Aortic dissection
- Hepatitis
- Pyelonephritis
- Pneumonia
- Pyogenic liver abscess
- Fitz-Hugh-Curtis Syndrome
- Hepatomegaly due to CHF
- Bowel obstruction
- SMA syndrome
- Pulmonary embolism
- Bezoar
- Ingested foreign body
Evaluation
- CBC (to rule out anemia)
- BMP, LFTs
- Lipase
- Consider:
- Acute abdominal series
- ?Barium swallow (upper GI series)
- Endoscopy (most will be done as outpatient)
- RUQ US
- ECG/troponin
Management
- Cessation of NSAIDs and ETOH
- Eradicate H. pylori if identified in symptomatic patient
- Triple Therapy: PPI + clarithromycin 500mg BID + amoxicillin1g BID x 10-14d
- Metronidazole 500mg BID can be substituted for amoxicillin in penicillin-allergic individuals
- Quadruple Therapy: PPI + bismuth subsalicylate 524mg QID + metronidazole 250mg QID and tetracycline 500mg QID x 10-14d.
- Can be used in areas of high resistance to clarithromycin or metronidazole
- Triple Therapy: PPI + clarithromycin 500mg BID + amoxicillin1g BID x 10-14d
- PPI
- Generally heal ulcers faster than H2 blockers
- Omeprazole 20-40mg QD
- H2 blockers
- Famotidine 20-40mg QD
- Ranitidine 75-150mg BID
Disposition
- Normally outpatient management, unless complication (see below)
Red Flags
Any of the following suggest need for endoscopy referral:
- Age >55yr
- Unexplained weight loss
- Early satiety
- Persistent vomiting
- Dysphagia
- Anemia or GI bleeding
- Abdominal mass
- Persistent anorexia
- Jaundice